A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
The “2024 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs. Additionally, 34 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Outlook Therapeutics announced March 22 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending approval of ONS-5010 (L...
Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...
OcuTerra Therapeutics announced March 14 that nesvategrast (OTT166 5%), its eye drop candidate for diabetic retinopathy, did not meet its primary or key secondary efficacy endpoints in the Phase II...
Nearly 7,800 delegates attended the 2024 congress of the Asia-Pacific Academy of Ophthalmology in southern Bali from Feb. 22-25. The 253 sessions and 120 exhibits spread across four floors in two n...
The Centers for Medicare and Medicaid Services (CMS) has issued J-codes for Regeneron’s Eylea HD and Astellas Pharma’s Izervay. The billing codes take effect April 1, 2024. Eylea HD (aflibercept) i...
Bascom Palmer Eye Institute reported March 5 that it would use a $1 million donation to fast-forward its initiative to transplant a whole eye. The hospital, part of the University of Miami, said th...
Artificial intelligence can accurately and independently detect 100 percent of severe cases of retinopathy of prematurity (ROP), according to a study published March 7 in the journal JAMA Ophthalmo...
Amring Pharmaceuticals announced March 4 that it had changed its name to Nordic Pharma Inc., following the change in ownership of the company from Sever Life Sciences to Nordic Group in June 2023. ...
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
A Multi-Step Approach for Accurate & Timely Data
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.